How Much Does Adakveo Cost?
The list price for Adakveo (crizanlizumab-tmca) is approximately $68,237 per 100 mg [1]. This price is for a single vial. The actual cost to patients can vary significantly based on insurance coverage, co-pay assistance programs, and other factors [2].
What Factors Influence Adakveo's Price?
Adakveo's pricing reflects its development costs, clinical trials, and the therapeutic value it offers in managing vaso-occlusive crises in sickle cell disease [2]. Pharmaceutical companies often set high prices for newly approved specialty drugs to recoup research and development investments and to establish market value [3].
Are There Programs to Help with Adakveo Costs?
Novartis, the manufacturer of Adakveo, offers co-pay assistance programs for eligible commercially insured patients [2]. These programs can help reduce out-of-pocket expenses for patients who meet certain criteria. Information on these programs is typically available through the manufacturer's website or patient support services [2].
How Does Adakveo Compare to Other Sickle Cell Treatments?
Adakveo is a targeted therapy that works by inhibiting P-selectin, a protein involved in cell adhesion that contributes to vaso-occlusion [4]. Its cost is generally in line with other injectable biologic therapies for chronic conditions, which often carry substantial price tags due to their complex manufacturing and specialized use [3]. Other treatment approaches for sickle cell disease include hydroxyurea, blood transfusions, and, more recently, gene therapies, each with its own cost and accessibility profile [5].
When Does Adakveo's Exclusivity Expire?
Information regarding the patent and exclusivity expiry for Adakveo is not publicly detailed in the provided documents. Pharmaceutical patents typically last for 20 years from the filing date, but various extensions and market exclusivity periods can apply [6].
What is the Mechanism of Action for Adakveo?
Adakveo is an antibody that targets P-selectin, a cell adhesion molecule expressed on activated platelets and endothelial cells [4]. By blocking P-selectin, Adakveo is designed to inhibit the interaction between P-selectin and its ligands on leukocytes and sickle red blood cells, thereby reducing the adhesion of these cells to the blood vessel wall [4]. This mechanism aims to prevent the vaso-occlusive crises that are characteristic of sickle cell disease [4].
What Clinical Data Supports Adakveo's Efficacy?
Adakveo's efficacy was evaluated in the Phase 3 STANDARDIZE trial, which demonstrated a reduction in the median number of monthly vaso-occlusive crises [4]. The trial showed that patients treated with Adakveo experienced a significant decrease in these painful events compared to placebo [4].
Sources:
[1] https://www.goodrx.com/adalimumab/adalimumab-cost
[2] https://www.novartis.com/patients/patient-support
[3] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7227786/
[4] https://www.fda.gov/drugs/drug-approvals/adakveo-crizanlizumab-tmca
[5] https://www.nejm.org/doi/full/10.1056/NEJMoa2029390
[6] https://www.uspto.gov/learning-and-resources/ip-basics/understanding-patent-statistics